Anti-VEGF treatment has revolutionized the management of vasoproliferative diseases of the retina, such as choroidal neovascularization associated with age related macular degeneration, proliferative diabetic retinopathy, macular edema associated with central retinal vein occlusion and neovascular glaucoma [12]. Here, VEGFA is linked to neovascular glaucoma.